RWE focus is shifting to R&D, early investments begin to payoff
How can others catch up?
Companies that have invested in mature RWE capabilities are seeing returns; others are behind. Results from Deloitte’s third RWE benchmarking study reveal how companies still building their capabilities can catch up.
2020 US and global life sciences outlook
Transforming pharmacovigilance systems
Using technology, analytics, and automation to enable next-gen patient safety
Lowering case processing costs, expanding signal processing capabilities, and expediting product safety reports are compelling reasons for biopharma companies to include automation, cognitive technologies, and advanced analytics in their PV budgets.